SCHEMBL4714911

SCHEMBL4714911

O=C(O)CC1Cc2ccccc2CCN1Cc1ccc(-c2ccccc2CNc2ccccn2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.37
BDKRB1 P46663 1/20 0.37
ITGB3 P05106 8/20 0.36
ITGAV P06756 8/20 0.36
ITGA2B P08514 6/20 0.36
ITGB5 P18084 5/20 0.36
ITGB1 P05556 2/20 0.36
ITGA5 P08648 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GHSR Q92847 2/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
HDAC1 Q13547 1/20 0.34
CXCR4 P61073 1/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714907 0.80 ITGB3 (0.42) CD274BDKRB1ITGB3ITGAVITGA2B
SCHEMBL4718825 0.72 ITGB3 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4716886 0.71 ITGB1 (0.42) ITGB3ITGAVITGB1ITGA5ALDH1A1
SCHEMBL4718126 0.71 ITGB3 (0.46) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4716851 0.69 DPP4 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718121 0.69 ITGB3 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718672 0.67 ITGB3 (0.47) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4715244 0.66 ITGB1 (0.40) ITGB1ITGA5DRD2MAPT
SCHEMBL8408488 0.59 GBA1 (0.48) ITGB1ITGA5ALDH1A1FFAR1
SCHEMBL3374151 0.59 CXCR4 (0.82) ALDH1A1HPGDHDAC1CXCR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed